GLP-1ra Pharmacokinetics and Clinical Effects: Focus on Cardiac, Vascular, and Glomerular Structures

INTRODUCTION: Glucagon-like peptide-1 receptor agonists (GLP-1RA) have emerged as key drug class in the management of the cardio-nephro-metabolic continuum. Their effects extend to cardiac, vascular, and renal systems, providing a pathophysiological basis for the results of cardiovascular outcomes trials. Their pharmacokinetic properties substantially contribute, as structural modifications prolonged plasma half-life and increased systemic exposure through resistance to enzymatic degradation, albumin binding, and optimization of molecular size. AREAS COVERED: This review integrates current evidence on pharmacokinetics, pharmacodynamics, and clinical effects of GLP-1RA focusing on the heart, vascular system, and kidney. A literature search until March 2026 was performed using MEDLINE, EMBASE, Google Scholar, Web of Science, and the Cochrane Controlled Trials Register. GLP-1RA exert modest chronotropic effects and cardiac protection in ischemia-reperfusion, although direct myocardial effects remain incompletely defined. Vascular benefits seem mediated by improved endothelial function, reduced oxidative stress, and modulation of nitric oxide pathways. In the kidney, GLP-1RA modulate proximal tubular sodium reabsorption and tubule-glomerular feedback, leading to reduced albuminuria and slower renal function decline. Clinical trials and meta-analyses documented reductions in major cardiovascular and renal outcomes. EXPERT OPINION: In our view, pharmacokinetics is a major determinant of the clinical profile of GLP-1RA, beyond glycemic control alone.